213 related articles for article (PubMed ID: 12006555)
41. Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL; McLeod HL
Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
[TBL] [Abstract][Full Text] [Related]
42. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
43. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
Magné N; Etienne-Grimaldi MC; Cals L; Renée N; Formento JL; Francoual M; Milano G
Br J Clin Pharmacol; 2007 Aug; 64(2):237-40. PubMed ID: 17335544
[TBL] [Abstract][Full Text] [Related]
44. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Saif MW; Seller S; Diasio RB
JOP; 2008 Mar; 9(2):226-9. PubMed ID: 18326935
[TBL] [Abstract][Full Text] [Related]
45. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
[TBL] [Abstract][Full Text] [Related]
46. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
Zhang X; Diasio RB
Pharmacogenomics; 2007 Mar; 8(3):257-65. PubMed ID: 17324113
[TBL] [Abstract][Full Text] [Related]
47. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; Van Gennip AH
Adv Exp Med Biol; 1998; 431():293-8. PubMed ID: 9598078
[No Abstract] [Full Text] [Related]
48. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
49. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Gardiner SJ; Begg EJ; Robinson BA
Adverse Drug React Toxicol Rev; 2002; 21(1-2):1-16. PubMed ID: 12140902
[TBL] [Abstract][Full Text] [Related]
50. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.
Sasaki H; Fukai I; Kiriyama M; Kaji M; Yano M; Yamakawa Y; Fujii Y
Surg Today; 2003; 33(2):83-8. PubMed ID: 12616366
[TBL] [Abstract][Full Text] [Related]
51. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
52. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
[TBL] [Abstract][Full Text] [Related]
53. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
54. Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Kobunai T; Ooyama A; Sasaki S; Wierzba K; Takechi T; Fukushima M; Watanabe T; Nagawa H
Eur J Cancer; 2007 Mar; 43(4):791-8. PubMed ID: 17254767
[TBL] [Abstract][Full Text] [Related]
55. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
Amstutz U; Froehlich TK; Largiadèr CR
Pharmacogenomics; 2011 Sep; 12(9):1321-36. PubMed ID: 21919607
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
57. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
58. [A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
Kobayashi K; Sumi S; Kidouchi K; Mizuno I; Mohri N; Fukui T; Akamo Y; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1217-9. PubMed ID: 9679586
[TBL] [Abstract][Full Text] [Related]
59. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
[TBL] [Abstract][Full Text] [Related]
60. Structural organization of the human dihydropyrimidine dehydrogenase gene.
Johnson MR; Wang K; Tillmanns S; Albin N; Diasio RB
Cancer Res; 1997 May; 57(9):1660-3. PubMed ID: 9135003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
